This report summarizes a completed COPD airway clearance trial comparing oscillating positive expiratory pressure therapy with autogenic drainage and explains potential regulatory implications.
The publication date context for this article is February 11, 2026. The trial record is listed on ClinicalTrials.gov and is sponsored by Adnan Hashim. The source_text indicates a head to head comparison of two airway clearance modalities in COPD, with an intervention described as an Oscillating Positive Expiratory Pressure Therapy device and a behavioral approach called Autogenic Drainage. No results are provided in the source_text, so current statements are limited to trial design and status.
What changed in COPD airway clearance research?
The ClinicalTrials.gov entry NCT07402850 lists two arms: Oscillating Positive Expiratory Pressure Therapy device and Autogenic Drainage. The status shown is completed and the sponsor is Adnan Hashim. The provided source_text does not include trial results. This points to a growing interest in head to head comparisons of airway clearance modalities in COPD and may inform future regulatory discussions about device indications and required training materials.
Trial design and status
Trial design details in the source_text focus on the condition COPD and the topic airway clearance. Interventions are a device based Oscillating Positive Expiratory Pressure Therapy and a behavioral Autogenic Drainage approach. The completion status indicates the study has ended, but endpoints and results are not included in the provided text. Readers should consult the ClinicalTrials.gov entry for endpoints, sample size, and results when they become available or are published, and they may reference the external link for the registry record.
Who is affected by this trial?
The trial targets patients with COPD seeking airway clearance options. Clinicians evaluating device options for COPD care may reference the trial design when considering patient selection and training needs. Regulators monitoring airway clearance technologies may view the trial in the context of device indications and post market obligations. The sponsor and completion status provide regulatory context and signal potential future submissions.
Stakeholders
Key stakeholder groups include COPD patients and their care teams, healthcare providers, device manufacturers, researchers, trial registries, and payer organizations evaluating new airway clearance tools.
What is the regulatory context for this trial?
Regulatory considerations for trials like this center on how results may influence device indications and safety disclosures. A MDR style approach requires clear statements about intended purpose and performance when a device is introduced or modified. The source_text confirms sponsor identity and completion status and provides a publicly accessible registry entry which supports transparency in the regulatory process. More on related topics can be found in our Regulatory Affairs Update linked here: Regulatory Affairs Update.
Intended purpose and disclosure
The source_text describes a comparison of two airway clearance modalities rather than a claim about superiority or specific performance. Any conclusions about effectiveness require published results. If outcomes were to support a regulatory submission the appropriate risk management and post market surveillance steps would apply as dictated by the MDR and national regulations.
What are the implications for patients and providers?
For clinicians the trial design highlights the ongoing interest in non pharmacologic airway clearance options for COPD. For device developers the study underscores the importance of transparent trial registration and clear modeling of intended use. For regulators the record underscores the need to monitor future publications and regulatory filings related to Oscillating Positive Expiratory Pressure Therapy devices and related Autogenic Drainage methods. See also our COPD Therapy Options post for broader context: COPD airway clearance options.
Next steps
Reading the trial record and any published results will be essential to determine device indications and clinical recommendations. Stakeholders should rely on peer reviewed publications and official regulatory submissions rather than preliminary press coverage. The next steps may include additional trials or analyses that provide robust safety and performance data.
FAQ
- 1. What is the study about? The study compares two airway clearance modalities in COPD: Oscillating Positive Expiratory Pressure Therapy and Autogenic Drainage.
- 2. Who sponsors the trial? Adnan Hashim.
- 3. Where can I find the trial record? On ClinicalTrials.gov at NCT07402850.
- 4. Are results available in the source_text? No results are provided in the source_text.
- 5. What is the regulatory relevance? The trial illustrates registry data use in regulatory thinking and the potential for future submissions.
Conclusion
In summary the completed COPD trial comparing Oscillating Positive Expiratory Pressure Therapy with Autogenic Drainage signals potential regulatory interest. Stakeholders should monitor for published results and regulatory filings, review the ClinicalTrials.gov entry, and consider implications for device indications and training. The absence of data in the source_text means no performance claims should be inferred at this time.
Disclaimer
This article is intended for professional readers and is not legal advice. It reflects analysis of the source_text and publicly available information. For formal regulatory guidance consult accredited sources and legal counsel as needed.
Announcement
For full information about the announcement, see the link below. On the next line place the link as a full URL.
https://clinicaltrials.gov/study/NCT07402850?term=medical+device